Loading...
XNAS
REGN
Market cap59bUSD
Apr 11, Last price  
554.18USD
1D
1.43%
1Q
-20.48%
Jan 2017
50.97%
Name

Regeneron Pharmaceuticals Inc

Chart & Performance

D1W1MN
P/E
13.50
P/S
4.20
EPS
41.04
Div Yield, %
—
Shrs. gr., 5y
0.09%
Rev. gr., 5y
12.55%
Revenues
14.20b
+8.27%
66,193,00063,447,000125,024,000238,457,000379,268,000459,074,000445,824,0001,378,477,0002,104,745,0002,819,557,0004,103,728,0004,860,427,0005,872,227,0006,710,800,0007,863,400,0008,497,100,00016,071,700,00012,172,900,00013,117,200,00014,202,000,000
Net income
4.41b
+11.61%
-95,446,000-102,337,000-105,600,000-82,710,000-67,830,000-104,468,000-221,760,000750,269,000424,362,000348,074,000636,056,000895,522,0001,198,511,0002,444,400,0002,115,800,0003,513,200,0008,075,300,0004,338,400,0003,953,600,0004,412,600,000
CFO
4.42b
-3.78%
-30,296,00023,075,00027,372,000-89,086,000-72,230,00096,344,000-141,682,000-74,615,000588,596,000752,435,0001,330,780,0001,485,900,0001,307,100,0002,195,100,0002,430,000,0002,618,100,0007,081,300,0005,014,900,0004,594,000,0004,420,500,000
Earnings
Apr 30, 2025

Profile

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
URL
https://www.regeneron.com/
IPO date
Apr 02, 1991
Employees
12,256
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
14,202,000
8.27%
13,117,200
7.76%
12,172,900
-24.26%
Cost of revenue
7,102,500
6,254,800
5,152,900
Unusual Expense (Income)
NOPBT
7,099,500
6,862,400
7,020,000
NOPBT Margin
49.99%
52.32%
57.67%
Operating Taxes
367,300
245,700
520,400
Tax Rate
5.17%
3.58%
7.41%
NOPAT
6,732,200
6,616,700
6,499,600
Net income
4,412,600
11.61%
3,953,600
-8.87%
4,338,400
-46.28%
Dividends
Dividend yield
Proceeds from repurchase of equity
(2,167,100)
(1,790,100)
(1,009,000)
BB yield
2.64%
1.79%
1.23%
Debt
Debt current
720,000
Long-term debt
3,424,400
3,422,900
3,421,400
Deferred revenue
126,700
69,800
Other long-term liabilities
1,757,100
854,100
(128,000)
Net debt
(5,588,100)
(12,818,400)
(15,599,100)
Cash flow
Cash from operating activities
4,420,500
4,594,000
5,014,900
CAPEX
(755,900)
(590,100)
Cash from investing activities
(2,468,100)
(3,185,100)
(3,784,600)
Cash from financing activities
(2,200,500)
(1,790,100)
(1,009,000)
FCF
5,650,600
6,478,800
6,273,200
Balance
Cash
9,012,500
10,844,800
14,334,100
Long term investments
5,396,500
5,406,400
Excess cash
8,302,400
15,585,440
19,131,855
Stockholders' equity
31,665,100
27,179,500
23,068,000
Invested Capital
25,512,700
14,071,360
6,895,045
ROIC
34.01%
63.12%
114.17%
ROCE
21.00%
23.14%
26.91%
EV
Common stock shares outstanding
115,100
113,700
113,500
Price
712.33
-18.90%
878.29
21.73%
721.49
14.25%
Market cap
81,989,183
-17.90%
99,861,573
21.95%
81,889,115
15.57%
EV
76,401,083
87,043,173
66,290,015
EBITDA
7,582,400
7,283,400
7,361,400
EV/EBITDA
10.08
11.95
9.01
Interest
55,200
73,000
59,400
Interest/NOPBT
0.78%
1.06%
0.85%